Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPARE: Stopping Pneumonia Antibiotherapy Regimen Early in Children
2024-512236-30-00Phase 3Authorised
- Sponsor
- Centre Hospitalier Universitaire de Montpellier
- Start
- Aug 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of amoxicillin in community-acquired pneumonia (CAP) and pneumonia (2 arms), sponsored by Centre Hospitalier Universitaire de Montpellier. Primary endpoint: Therapeutic failure rate on Day 7. Planned start Aug 2024; status: authorised.
02
Drugs
amoxicillin
03
Conditions
community-acquired pneumonia (CAP)pneumonia
Beyond the preview
Go deeper on 2024-512236-30-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512236-30-00.